

## PLAINTIFFS' EXHIBIT LIST

Page 1 of 177

Case # 2:16-cv-02525-MMD-NJKCaption: Amarin Pharma Inc. et al. v. Hikma Pharmaceuticals USA, Inc. et al.

Date Marked	Date Admitted	Number	Witness	Description
		1		335 Patent Assignment, (AMRN00289793 – AMRN00289803)
		2		372 Patent Assignment, (AMRN00289862 – AMRN00289868)
		3		372 Patent Assignment, (AMRN00289869 – AMRN00289870)
		4		399 Patent Assignment, (AMRN00289804 – AMRN00289814)
		5		446 Patent Assignment, (AMRN00289782 – AMRN00289792)
		6		521 Patent Assignment, (AMRN00289871 – AMRN00289877)
11/13/2020	11/13/2020	7		560 Patent Assignment, (AMRN00289815 – AMRN00289825)
<i>stipulated</i>				

Date Marked	Date Admitted	Number	Witness	Description
		8		594 Patent Assignment, (AMRN00289878 – AMRN00289884)
		9		650 Patent Assignment, (AMRN00289826 – AMRN00289836)
1/13/2020	1/13/2020	10		652 Patent Assignment, (AMRN00289760 – AMRN00289770)
<i>Stipulated</i>				
1/13/2020	1/13/2020	11		677 Patent Assignment, (AMRN00289749 – AMRN00289759)
<i>Stipulated</i>				
		12		698 Patent Assignment, (AMRN00289853 – AMRN00289859)
		13		698 Patent Assignment, (AMRN00289860 – AMRN00289861)
1/13/2020	1/13/2020	14		715 Patent Assignment, (AMRN00289738 – AMRN00289748)
<i>Stipulated</i>				
1/13/2020	1/13/2020	15		728 Patent Assignment, (AMRN00289727 – AMRN00289737)
<i>Stipulated</i>				

Date Marked	Date Admitted	Number	Witness	Description
		16		920 Patent Assignment, (AMRN00289771 – AMRN00289781)
1/13/2020	1/13/2020	17		929 Patent Assignment, (AMRN00289844 – AMRN00289850)
			<i>Stipulated</i>	
1/13/2020	1/13/2020	18		929 Patent Assignment, (AMRN00289851 – AMRN00289852)
			<i>Stipulated</i>	
		19		225 Patent Assignment, (AMRN00289837 – AMRN00289843)
1/13/2020	1/13/2020	20		U.S. Patent No. 8,293,727, (AMRN03061427 – AMRN03061447)
			<i>20/1520 are the same 20/1520 is stipulated as admitted 1/13/2020</i>	
1/13/2020	1/13/2020	21		U.S. Patent No. 8,293,728, (AMRN-PEXP-0000001 – AMRN-PEXP-0000022)
			<i>21/1500 are the same 21/1500 is stipulated as admitted 1/13/2020</i>	
1/13/2020	1/13/2020	22		U.S. Patent No. 8,318,715 & Certificate of Correction, (AMRN-PEXP-0000023 – AMRN-PEXP-0000045)
			<i>22/1502 are the same 22/1502 is stipulated as admitted 1/13/2020</i>	
1/13/2020	1/13/2020	23		U.S. Patent No. 8,318,715 Approval of Certificate of Correction (filed Mar. 26, 2019), (AMRN-PEXP-0008411 – AMRN-PEXP-0008411)
			<i>Stipulated</i>	

Date Marked	Date Admitted	Number	Witness	Description
1/13/2020	1/13/2020	24		U.S. Patent No. 8,318,715 Request for Certificate of Correction (filed Mar. 26, 2019), (AMRN-PEXP-0008412 – AMRN-PEXP-0008414)  <i>stipulated</i>
1/13/2020	1/13/2020	25		U.S. Patent No. 8,357,677, (AMRN-PEXP-0000046 – AMRN-PEXP-0000067)  <i>25/1504, <sup>are the same</sup> is stipulated as admitted 1/13/2020</i>
1/13/2020	1/13/2020	26		U.S. Patent No. 8,367,652, (AMRN-PEXP-0000068 – AMRN-PEXP-0000090)  <i>26/1506, <sup>are the same</sup> is stipulated as admitted 1/13/2020</i>
1/13/2020	1/13/2020	27		U.S. Patent No. 8,377,920, (AMRN-PEXP-0000091 – AMRN-PEXP-0000113)  <i>27/1508 is stipulated as admitted 1/13/2020</i>
1/13/2020	1/13/2020	28		U.S. Patent No. 8,399,446, (AMRN-PEXP-0000114 – AMRN-PEXP-0000136)  <i>28/1510 is stipulated as admitted 1/13/2020</i>
1/13/2020	1/13/2020	29		U.S. Patent No. 8,415,335, (AMRN-PEXP-0000137 – AMRN-PEXP-0000160)  <i>29/1512 is stipulated as admitted 1/13/2020</i>
1/13/2020	1/13/2020	30		U.S. Patent No. 8,431,560, (AMRN-PEXP-0000161 – AMRN-PEXP-0000183)  <i>30/1514, is stipulated as adm. filed 1/13/2020</i>
1/13/2020	1/13/2020	31		U.S. Patent No. 8,518,929, (AMRN-PEXP-0000184 – AMRN-PEXP-0000206)  <i>31/1516 is stipulated as admitted 1/13/2020</i>

Date Marked	Date Admitted	Number	Witness	Description
1/13/2020	1/13/2020	32		U.S. Patent No. 8,524,698 & Certificate of Correction, (AMRN-PEXP-0000207 – AMRN-PEXP-0000230)
			3211518 is admitted by stipulation 1/13/2020	
1/13/2020	1/13/2020	33		U.S. Patent No. 8,426,399
			Stipulated	
1/13/2020	1/13/2020	34		U.S. Patent No. 8,426,399 Certificate of Correction
			Stipulated	
1/13/2020	1/13/2020	35		U.S. Patent No. 8,440,650
			Stipulated	
1/13/2020	1/13/2020	36		U.S. Patent No. 8,546,372
			Stipulated	
1/13/2020	1/13/2020	37		U.S. Patent No. 8,617,594
			Stipulated	
1/13/2020	1/13/2020	38		File History of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889), (AMRN03058106 – AMRN03059969)
		3811521 is stipulated as admitted 1/13/2020		
1/13/2020	1/13/2020	39		File History of U.S. Patent No. 8,293,728, (AMRN00206053 – AMRN00212773)
		3911501 is stipulated as admitted 1/13/2020		

Date Marked	Date Admitted	Number	Witness	Description
1/13/2020	1/13/2020	40		File History of U.S. Patent No. 8,318,715 & Certificate of Correction, (AMRN00212774 – AMRN00219280)  40/1503 is stipulated as admitted 1/13/2020
1/13/2020	1/13/2020	41		File History of U.S. Patent No. 8,357,677, (AMRN00219281 – AMRN00225724)  41/1505 is stipulated as admitted 1/13/2020
1/13/2020	1/13/2020	42		File History of U.S. Patent No. 8,367,652, (AMRN00225725 – AMRN00232139)  42/1507 is stipulated as admitted 1/13/2020
		43		File History of U.S. Patent No. 8,377,920, (AMRN00232140 – AMRN00239831)
		44		File History of U.S. Patent No. 8,399,446, (AMRN00239832 – AMRN00247573)
		45		File History of U.S. Patent No. 8,415,335, (AMRN00247574 – AMRN00255303)
		46		File History of U.S. Patent No. 8,426,372 (“the ‘372 Patent”), (AMRN00288609 – AMRN00288853)
		47		File History of U.S. Patent No. 8,426,399 (“the ‘399 Patent”), (AMRN00255304 – AMRN00263073)

Date Marked	Date Admitted	Number	Witness	Description
		48		File History of U.S. Patent No. 8,426,594 ("the '594 Patent"), (AMRN00289112 – AMRN00289726)
		49		File History of U.S. Patent No. 8,426,650 ("the '650 Patent"), (AMRN00271242 – AMRN00279417)
1/13/2020	1/13/2020	50		File History of U.S. Patent No. 8,431,560, (AMRN00263074 – AMRN00271241)  50/1515 is stipulated as admitted 1/13/2020
1/13/2020	1/13/2020	51		File History of U.S. Patent No. 8,518,929, (AMRN00287378 – AMRN00287988)  51/1517 is stipulated as admitted 1/13/2020
		52		File History of U.S. Patent No. 8,524,698 & Certificate of Correction, (AMRN00287989 – AMRN00288608)
1/13/2020	1/13/2020	53		Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (Jan. 8, 2012) ("Bays Decl. II"), (AMRN03059316 – AMRN03059331)  stipulated 1/13/2020
		54		Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 13/349,153) (June 6, 2012) ("Bays Decl. IV"), (AMRN00212350 – AMRN00212359)
1/13/2020	1/13/2020	55		Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 18, 2011), (AMRN03058234 – AMRN03058253)  stipulated

Date Marked	Date Admitted	Number	Witness	Description
		56		Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 18, 2011), (AMRN03058234 – AMRN03059940)
1/13/2020	1/13/2020	57		Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 8, 2012) ("Bays Decl. III"), (AMRN03059815 – AMRN03059823) <i>stipulated</i>
1/13/2020	1/13/2020	58		Howard Weintraub Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 26, 2011) ("Weintraub Decl. I"), (AMRN03058275 – AMRN03058277) <i>stipulated</i>
1/13/2020	1/13/2020	59		Howard Weintraub Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (Sept. 19, 2011), (AMRN03059081 – AMRN03059228) <i>stipulated</i>
1/13/2020	1/13/2020	60		715 Patent Certificate of Correction (May 21, 2019), (AMRN-PEXP-0009764 – AMRN-PEXP-0009764) <i>stipulated</i>
		61		FDA Correspondence dated July 23, 2018, (DRLEEEPA 0097312 – DRLEEEPA 0097344)
		62		Letter from R. Krishna to Office of Generic Drugs (Aug. 29, 2018), (DRLEEEPA 0137849 – DRLEEEPA 0137888)

Date Marked	Date Admitted	Number	Witness	Description
		63		Manual of Patent Examining Procedure (MPEP), Eighth Edition Revisions 8 and 9, including sections cited in Report, available at <a href="http://www.uspto.gov/web/offices/pac/mpep/">http://www.uspto.gov/web/offices/pac/mpep/</a> .
		64		International Patent Application No. WO 02/02105 A1, (ICOSAPENT_DFNDTS00013779 – ICOSAPENT_DFNDTS00013807)
		65		ANDA No. 209499 - Forms and Cover Letter (Modules 1.1-1.2), (DRLEEP A 0000001 – DRLEEP A 0000034)
		66		ANDA No. 209499 - Administrative Information, (DRLEEP A 0000035 – DRLEEP A 0000056)
		67		ANDA No. 209499 - References (Module 1.4), (DRLEEP A 0000057 – DRLEEP A 0000068)
		68		ANDA No. 209499 - Other Correspondence (Module 1.12), (DRLEEP A 0000069 – DRLEEP A 0000077)
1/13/2020	1/13/2020	69		ANDA No. 209499 - Labeling (Module 1.14), (DRLEEP A 0000078 – DRLEEP A 0000162)
<i>Stipulated</i>				

Date Marked	Date Admitted	Number	Witness	Description
		70		ANDA No. 209499 - CTD Summaries (Module 2), (DRLEEEPA 0000163 – DRLEEEPA 0000336)
		71		ANDA No. 209499 - Bioavailability and Bioequivalence Reports (Module 5.3), (DRLEEEPA 0000337 – DRLEEEPA 0000357)
		72		ANDA No. 209499 - Quality (Module 3), (DRLEEEPA 0000358 – DRLEEEPA 0002565)
		73		ANDA No. 209499 - Correspondence dated Sept. 8, 2016, (DRLEEEPA 0002706 – DRLEEEPA 0002903)
		74		Email from R. Srinivasa to A. Patel et al. (Nov. 9, 2017), (DRLEEEPA 0097345 – DRLEEEPA 0097345)
		75		Letter from U. Chaudhry (FDA) to S. Rao (Nov. 9, 2017), (DRLEEEPA 0097346 – DRLEEEPA 0097348)
		76		Email from S. Rao to R. Yalla et al. (Nov. 30, 2017), (DRLEEEPA 0097349 – DRLEEEPA 0097349)
		77		Letter from D. Toyer McKan (FDA) to S. Rao (Nov. 29, 2017), (DRLEEEPA 0097350 – DRLEEEPA 0097352)

Date Marked	Date Admitted	Number	Witness	Description
		78		Letter from U. Chaudhry to S. Rao (Nov. 30, 2017), (DRLEEEPA 0097353 – DRLEEEPA 0097357)
		79		Letter from D. Toyer McKan to S. Rao (Jan. 7, 2019), (DRLEEEPA 0137834 – DRLEEEPA 0137838)
		80		FDA Correspondence - Form 356(h), (DRLEEEPA 0137842 – DRLEEEPA 0137848)
		81		Email from H. La to R. Yalla (Oct. 17, 2018), (DRLEEEPA 0137890 – DRLEEEPA 0137892)
		82		Email from D. Marchuk to R. Yalla (Nov. 14, 2018), (DRLEEEPA 0137893 – DRLEEEPA 0137894)
		83		Email from C. Cottle-Delisle to G. Prasad (Dec. 27, 2018), (DRLEEEPA 0137895 – DRLEEEPA 0137898)
		84		Email from S. Rao to C. Cottle-Delisle (Dec. 27, 2018), (DRLEEEPA 0137899 – DRLEEEPA 0137901)
		85		Email from G. Prasad to C. Cottle-Delisle (Dec. 27, 2018), (DRLEEEPA 0137902 – DRLEEEPA 0137905)

Date Marked	Date Admitted	Number	Witness	Description
		86		Letter from D. Toyer McKan to S. Rao (Jan. 7, 2019), (DRLEEPA 0137906 – DRLEEPA 0137910)
		87		FDA Correspondence dated July 30, 2019, (DRLEEPA 0137911 – DRLEEPA 0137920)
		88		Letter from R. Yalla to Office of Generic Drugs (Jul. 30, 2019), (DRLEEPA 0137921 – DRLEEPA 0137922)
		89		Letter from D. Toyer McKan to S. Rao (Jan. 7, 2019), (DRLEEPA 0137923 – DRLEEPA 0137927)
		90		Letter from C. Krumbholz to FDA (Jan. 24, 2019), (DRLEEPA 0137928 – DRLEEPA 0137929)
		91		FDA Correspondence dated Jan. 7, 2019, (DRLEEPA 0137930 – DRLEEPA 0137931)
		92		FDA Correspondence dated Jan. 7, 2019 (Attachment 1), (DRLEEPA 0137932 – DRLEEPA 0137982)
		93		FDA Correspondence dated Jan. 7, 2019 (Attachment 2), (DRLEEPA 0137983 – DRLEEPA 0138049)

Date Marked	Date Admitted	Number	Witness	Description
		94		Summary Report for Data Comparison of Impurities and Oligomers (July 2019), (DRLEEPA 0138050 – DRLEEPA 0138081)
		95		ANDA Section 3.2: Drug Substance, (DRLEEPA 0138082 – DRLEEPA 0138084)
		96		Certificate of Analysis dated June 25, 2019, (DRLEEPA 0138085 – DRLEEPA 0138106)
		97		eCTD DTD version 3.2, (DRLEEPA 0138108 – DRLEEPA 0138108)
		98		Letter from D. Marchuk to S. Rao (Aug. 5, 2019), (DRLEEPA 0138109 – DRLEEPA 0138110)
		99		ANDA No. 209457 - Forms and Cover Letter, (WWIC0-NV-000028 – WWIC0-NV-000068)
		100		ANDA No. 209457 - Administrative Information (Module 1.3), (WWIC0-NV-000069 – WWIC0-NV-000084)
		101		ANDA No. 209457 - References (Module 1.4), (WWIC0-NV-000085 – WWIC0-NV-000097)

Date Marked	Date Admitted	Number	Witness	Description
		102		ANDA No. 209457 - Other Correspondence (Module 1.12), (WWIC0-NV-000098 – WWIC0-NV-000103)
1/13/2020	1/13/2020	103		ANDA No. 209457 - Labeling (Module 1.14), (WWIC0-NV-000104 – WWIC0-NV-000163)  <i>Supplemented</i>
		104		ANDA No. 209457 - CTD Summaries (Module 2), (WWIC0-NV-000164 – WWIC0-NV-000414)
		105		ANDA No. 209457 - Quality (Module 3), (WWIC0-NV-000415 – WWIC0-NV-002156)
		106		ANDA No. 209457 - Bioavailability and Bioequivalence Reports (Module 5), (WWIC0-NV-002157 – WWIC0-NV-002410)
		107		FDA Correspondence dated Sept. 7, 2016, (WWIC0-NV-002411 – WWIC0-NV-002855)
		108		West-Ward Certificate of Analysis Lot No. 3079110A (June 8, 2017), (WWICO-NV-099995 – WWICO-NV-099995)
		109		West-Ward Certificate of Analysis Lot No. 1362418 (July 19, 2016), (WWICO-NV-099994 – WWICO-NV-099994)

Date Marked	Date Admitted	Number	Witness	Description
		110		Letter from T. Adams (FDA) to S. Smith (Hikma) (April 2017), (WWICO-NV-099952 – WWICO-NV-099956)
		111		Email from T. Adams (FDA) to S. Smith (Hikma) (May 2, 2017), (WWICO-NV-099957 – WWICO-NV-099957)
		112		eCTD DTD version 3.2, (WWICO-NV-099958 – WWICO-NV-099959)
		113		ANDA 209457 FDA Application to Market a New or Abbreviated New Drug or Biologic for Human Use (June 15, 2017), (WWICO-NV-099963 – WWICO-NV-099967)
		114		Letter from S. Smith (Hikma) to T. Adams (FDA) (June 15, 2017), (WWICO-NV-099968 – WWICO-NV-099969)
		115		Letter from T. Adams (FDA) to S. Smith (Hikma) (April 2017), (WWICO-NV-099970 – WWICO-NV-099974)
		116		FDA ANDA Correspondence - Quality, (WWICO-NV-099975 – WWICO-NV-099993)
		117		Raw Material Specification, (WWICO-NV-099996 – WWICO-NV-099999)

Date Marked	Date Admitted	Number	Witness	Description
		118		Supplemental Validation Report, (WWICO-NV-100000 – WWICO-NV-100012)
		119		Certificate of Analysis Lot No. A2008, (WWICO-NV-100013 – WWICO-NV-100014)
		120		Certificate of Analysis Lot No. A4001, (WWICO-NV-100015 – WWICO-NV-100016)
		121		Certificate of Analysis Lot No. A5005, (WWICO-NV-100017 – WWICO-NV-100020)
<del>122</del>		122		Raw Material Specification, (WWICO-NV-100021 – WWICO-NV-100022)
		123		West-Ward Specification - Icosapent Ethyl Capsules, 1 gram, (WWICO-NV-100023 – WWICO-NV-100025)
		124		Finished Products Test Method, (WWICO-NV-100026 – WWICO-NV-100040)
		125		West-Ward Analytical Procedure, (WWICO-NV-100041 – WWICO-NV-100048)

Date Marked	Date Admitted	Number	Witness	Description
		126		Signature Page, (WWICO-NV-100049 – WWICO-NV-100059)
		127		Report (June 6, 2017), (WWICO-NV-100060 – WWICO-NV-100068)
		128		Dissolution Data dated June 9, 2017, (WWICO-NV-100069 – WWICO-NV-100082)
		129		Dissolution Data dated June 6, 2017, (WWICO-NV-100083 – WWICO-NV-100105)
		130		Impurity Report dated May 18, 2017, (WWICO-NV-100106 – WWICO-NV-100124)
		131		Report dated June 1, 2017, (WWICO-NV-100125 – WWICO-NV-100151)
		132		West-Ward Certificate of Analysis, (WWICO-NV-100152 – WWICO-NV-100154)
		133		Stability Protocol, (WWICO-NV-100155 – WWICO-NV-100156)

Date Marked	Date Admitted	Number	Witness	Description
		134		Solutions Stability Summary Report, (WWICO-NV-100157 – WWICO-NV-100160)
		135		West-Ward Stability Data (June 6, 2017), (WWICO-NV-100161 – WWICO-NV-100168)
		136		40/75 Blank Table: Icosapent Ethyl Capsules, 1 gram, (WWICO-NV-100169 – WWICO-NV-100170)
		137		FDA Correspondence dated June 27, 2018, (WWICO-NV-162295 – WWICO-NV-162299)
		138		eCTD 3.2, (WWICO-NV-162310 – WWICO-NV-162310)
		139		ANDA No. 209457 eCTD, (WWICO-NV-162311 – WWICO-NV-162311)
		140		FDA Correspondence dated Sept. 28, 2018, (WWICO-NV-162312 – WWICO-NV-162316)
		141		Email from C. Koukoutsis to U. Chaudhry (Sept. 28, 2018), (WWICO-NV-162317 – WWICO-NV-162318)

Date Marked	Date Admitted	Number	Witness	Description
		142		Letter from T. Adams to S. Smith (April 2017), (WWICO-NV-162319 – WWICO-NV-162323)
		143		Email from T. Adams to S. Smith (May 2, 2017), (WWICO-NV-162324 – WWICO-NV-162324)
		144		Letter from D. Toyer McKan to S. Smith (Oct. 25, 2017), (WWICO-NV-162325 – WWICO-NV-162330)
		145		Letter from C. Jacobs to J. Andry (Oct. 3, 2018), (WWICO-NV-162331 – WWICO-NV-162333)
		146		FDA Correspondence dated Nov. 28, 2018, (WWICO-NV-162448 – WWICO-NV-162452)
		147		Letter from T. Adams to J. Andry (Apr. 3, 2019), (WWICO-NV-162453 – WWICO-NV-162456)
		148		FDA correspondence (undated), (WWICO-NV-162457 – WWICO-NV-162458)
		149		Letter from J. Connell to T. Adams (Apr. 11, 2019), (WWICO-NV-162459 – WWICO-NV-162459)

Date Marked	Date Admitted	Number	Witness	Description
		150		FDA Correspondence dated April 11, 2019, (WWICO-NV-162460 – WWICO-NV-162464)
		151		Letter from D. Toyer McKan to J. Andry (Jun. 10, 2019), (WWICO-NV-162465 – WWICO-NV-162469)
		152		FDA Correspondence dated July 18, 2019, (WWICO-NV-162470 – WWICO-NV-162474)
		153		Letter from J. Connell to C. Jacobs (Jul. 18, 2019), (WWICO-NV-162475 – WWICO-NV-162475)
		154		ANDA No. 209457: Bioequivalence, (WWICO-NV-162476 – WWICO-NV-162480)
		155		FDA Correspondence dated July 4, 2019, (WWICO-NV-162481 – WWICO-NV-162487)
		156		FDA Correspondence dated June 10, 2019, (WWICO-NV-162488 – WWICO-NV-162493)
		157		Certificate of Analysis (July 2019), (WWICO-NV-162494 – WWICO-NV-162494)

Date Marked	Date Admitted	Number	Witness	Description
		158		Certificate of Analysis (July 2019), (WWICO-NV-162495 – WWICO-NV-162495)
		159		Bhatt et al., <i>Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles</i> , J Am Coll Cardiol. 2019 Aug 27;74(8):1159-1161.
		160		Gupta et al., <i>An update on pharmacotherapies in diabetic dyslipidemia</i> , Prog Cardiovasc Dis. 2019 Aug 20. pii: S0033-0620(19)30105-7.
		161		Patel et al., <i>Cardiovascular risk reduction with icosapent ethyl</i> , Curr Opin Cardiol. 2019 Aug 28.
1/17/2020	1/17/2020	162	Fisher	American Diabetes Association, 10. <i>Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes--2019</i> , Diabetes Care 2019;42(Suppl. 1); 5103-5123, (AMRN-PEXP-0008656 – AMRN-PEXP-0008681)
		163		Mach et al., <i>2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk</i> , 00 European Heart Journal 1-78 (2019).
		164		National Lipid Association, <i>NLA Position on the Use of Icosapent Ethyl in High and Very-high-risk Patients</i> , National Lipid Association (Sept. 13, 2019).

Date Marked	Date Admitted	Number	Witness	Description
		165		Skulas-Ray et al., <i>Omega-3 Fatty Acids for the Management of Hypertriglyceridemia</i> , 140 Circulation e673 (2019).
		166		Corrected Opening Expert Report of Dr. Firhaad Ismail, M.D., F.A.C.E. (June 21, 2019)
		167		Expert Report of Sean Nicholson (March 11, 2019)
		168		Expert Report of Stephen G. Kunin (Responsive) (May 10, 2019)
		169		Opening Expert Report of Dr. Firhaad Ismail, M.D., F.A.C.E. (January 9, 2019)
		170		Opening Expert Report of Dr. Jonathan Curtis, Ph. D. (DRL/VASCEPA) (March 11, 2019)
		171		Opening Expert Report of Dr. Jonathan Curtis, Ph. D. (Hikma/VASCEPA) (March 11, 2019)
		172		Opening Expert Report of Dr. Matthew Budoff, M.D., Regarding DRL's ANDA Product And VASCEPA (March 11, 2019)

Date Marked	Date Admitted	Number	Witness	Description
		173		Opening Expert Report of Dr. Matthew Budoff, M.D., Regarding Hikma's ANDA Product And VASCEPA (March 11, 2019)
		174		Opening Expert Report of Peter Paul Toth, M.D., Ph. D. (March 7, 2019)
		175		Opening Expert Report of R. Preston Mason, Ph. D. (March 08, 2019)
		176		Reply Expert Report of Firhaad Ismail, M.D. , F.A.C.E. (June 10, 2019)
		177		Reply Expert Report of Matthew Budoff, M.D., Regarding Defendants' ANDA Products and VASCEPA (June 10, 2019)
		178		Reply Expert Report of Peter Toth, M.D., Ph.D. (June 10, 2019)
		179		Reply Expert Report of R. Preston Mason, Ph.D. (June 10, 2019)
		180		Reply Expert Report of Sean Nicholson (June 10, 2019)

Date Marked	Date Admitted	Number	Witness	Description
		181		Responsive Expert Report of Peter Toth, M.D., Ph. D. (May 10, 2019)
		182		Surreply Expert Report of Rebecca A. Betensky, Ph. D. (Aug. 22, 2019)
		183		Reply Expert Report of Carl C. Peck, M.D. (June 10, 2019)
		184		Hikma Pharmaceuticals' Rule 26(a)(1) Initial Disclosures
1/13/2020	1/13/2020	185		Notice of 30(b)(6) Deposition
1/13/2020	1/13/2020	186		Notice of Deposition of Jerald Andry
1/13/2020	1/13/2020	187		Proposed Package Label for Icosapent Ethyl (July 2016), (WWIC0-NV-000104 WWIC0-NV-000105) <i>Stipulated</i>
1/13/2020	1/13/2020	188		Proposed Package Insert For Icosapent Ethyl (July 2016), (WWIC0-NV-000109 WWIC0-NV-000117) <i>Stipulated</i>

Date Marked	Date Admitted	Number	Witness	Description
1/13/2020	1/13/2020	189		Side-by-Side Comparison of Insert/Outsert for Icosapent Ethyl, (WWIC0-NV-000139 – WWIC0-NV-000149) <i>Stipulated</i>
1/13/2020	1/13/2020	190		Highlights of Prescribing Information for VASCEPA, (WWIC0-NV-000151 – WWIC0-NV-000162) <i>Stipulated</i>
		191		Correspondence between Sarah A. Smith to Rhonda Rowell (Sept. 7, 2016), (WWIC0-NV-002423 – WWIC0-NV-002427)
1/13/2020	1/13/2020	192		Letter from S. Smith to S. Pyon (Jan. 10, 2017), (WWIC0-NV-002805 – WWIC0-NV002806)
1/13/2020	1/13/2020	193		Letter from S. Pyon to S. Smith (Dec. 23, 2016), (WWIC0-NV-002807 – WWIC0-NV-002809)
1/13/2020	1/13/2020	194		Revised Proposed Package Label For Icosapent Ethyl (December 2016), (WWIC0-NV-002844 – WWIC0-NV-002844) <i>Stipulated</i>
1/13/2020	1/13/2020	195		ANDA 209457: Labeling, (WWIC0-NV-002810 – WWIC0-NV-002812) <i>Stipulated</i>
1/13/2020	1/13/2020	196		Email from J. Andry to T. Amann et al. (May 15, 2013), (WWICO-NV-056968 – WWICO-NV-056969)

Date Marked	Date Admitted	Number	Witness	Description
		197		FDA Correspondence (Dec. 8, 2016), (WWICO-NV-000010 – WWICO-NV-000027)
1/13/2020	1/13/2020	198		ANDA Original Application 206264 (Nov. 15, 2013), (WWICO-NV-002877 – WWICO-NV-002878)
		199		Letter from S. Smith to T. Adams (June 15, 2017), (WWICO-NV-099968 – WWICO-NV-099993)
		200		Email from M. Annibaldi to S. Smith et al. (Sept. 7, 2016), (WWICO-NV-107615 – WWICO-NV-107618)
		201		FDA Form 356h West-Ward Pharmaceuticals Corp. Application For Name Change to Hikma Pharmaceuticals USA (June 27, 2018), (WWICO-NV-162295 – WWICO-NV-162302)
		202		Waiver Request from Dr. Reddy's (July 25, 2016), (DRLEEEPA 0000076 – DRLEEEPA 0000077)
1/13/2020	1/13/2020	203		Dr. Reddy's Icosapent Ethyl Description, (DRLEEEPA 0000125 – DRLEEEPA 0000148)
<i>Stipulated</i>				
		204		Icosapent Ethyl Capsules, 1g Abbreviated ANDA Quality Overall Summary, (DRLEEEPA 0000223 – DRLEEEPA 0000282)

Date Marked	Date Admitted	Number	Witness	Description
		205		Dr. Reddy's Batch Analysis, (DRLEEEPA 0000868 – DRLEEEPA 0000958)
1/13/2020	1/13/2020	206		Letter to Office of Generic Drugs from Dr. Reddy's (Jan. 4, 2017), (DRLEEEPA 0002801 – DRLEEEPA 0002807)
<i>Stipulated</i>				
1/13/2020	1/13/2020	207		Icosapent Ethyl Highlights of Prescribing Information, (DRLEEEPA 0002827 – DRLEEEPA 0002838)
<i>Stipulated</i>				
1/13/2020	1/13/2020	208		FDA correspondence dated December 23, 2016, (DRLEEEPA 0002895 – DRLEEEPA 0002897)
<i>Stipulated</i>				
		209		Letter from T. Adams (FDA) to S. Rao (April 2017), (DRLEEEPA 0013771 – DRLEEEPA 0013775)
1/13/2020	1/13/2020	210		Letter from Dr. Reddys to FDA dated March 29, 2013, (DRLEEEPA 0013799 – DRLEEEPA 0013804)
		211		Letter from Dr. Reddy's to Office of Generic Drugs (June 15, 2017), (DRLEEEPA 0016400 – DRLEEEPA 0016401)
		212		FDA Correspondence dated April 13, 2017, (DRLEEEPA 0016403 – DRLEEEPA 0016412)

Date Marked	Date Admitted	Number	Witness	Description
		213		Specification Reports, (DRLEEEPA 0016422 – DRLEEEPA 0016433)
1/13/2020	1/13/2020	214		FDA Correspondence Dated Oct. 25, 2017, (DRLEEEPA 0016912 – DRLEEEPA 0016917) <i>stipulated</i>
		215		Letter to Office of Generic Drugs from Dr. Reddy's (Nov. 2, 2017), (DRLEEEPA 0016935 – DRLEEEPA 0016942)
1/13/2020	1/13/2020	216		Email from A. Patel to A. Karunakar et al. (May 31, 2016), (DRLEEEPA 0031208 – DRLEEEPA 0031209)
1/13/2020	1/13/2020	217		ANDA No. 205616 Correspondence from FDA (undated), (DRLEEEPA 0031210 – DRLEEEPA 0031211)
		218		Document Produced in Native Format Placeholder, (DRLEEEPA 0031892 – DRLEEEPA 0031892)
1/13/2020	1/13/2020	219		Email from S. Bhamare to H. Ahmed et al. (July 27, 2016), (DRLEEEPA 0034257 – DRLEEEPA 0034260)
		220		Email from J. Singh to H. Ahmed (June 13, 2016), (DRLEEEPA 0031890 – DRLEEEPA 0031891)

Date Marked	Date Admitted	Number	Witness	Description
		221		ANDA Document Tracker & Related Spreadsheets, (DRLEEPA 0059163 – DRLEEPA 0059163)
		222		ANDA Document Tracker & Related Spreadsheets, (DRLEEPA 0076086 – DRLEEPA 0076086)
		223		Application to Market a New or Abbreviated New Drug or Biologic for Human Use, (DRLEEPA 0095538 – DRLEEPA 0095575)
		224		Email from A. Allen to U. Topiwala et al. (May 31, 2016), (DRLEEPA 0124709 – DRLEEPA 0124726)
		225		Amarin's Notice of Deposition Under 30(b)(6) to DRL
1/13/2020	1/13/2020	226		Email from D. Shelhoff to A. Whitt et al. re: Amarin Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc. et al., 16-cv-2525 (Oct. 8, 2018)
1/13/2020	1/13/2020	227		Notice of Deposition of Jaya Lakshmi Ayyagari
1/13/2020	1/13/2020	228		ANDA No. 209499, Submission of ANDA Application, (DRLEEPA 0000024 – DRLEEPA 0000030)

Date Marked	Date Admitted	Number	Witness	Description
		229		Icosapent, Ethyl Capsule 1g, <i>Finished Product Release Specifications</i> , (DRLEEP A 0016874 – DRLEEP A 0016878)
		230		USPTO Office Action Summary (March 2, 2012), (AMRN03059744 – AMRN03059769)
		231		Kornak V3 Coding, (AMRN-PEXP-0011080 – AMRN-PEXP-0011097)
		232		Kornak V3 Calculations, (AMRN-PEXP-0011098 – AMRN-PEXP-0011119)
		233		Kornak V5 Coding, (AMRN-PEXP-0011120 – AMRN-PEXP-0011131)
		234		Kornak V5 Calculations, (AMRN-PEXP-0011132 – AMRN-PEXP-0011145)
		235		Redline of Kornak V3 & V5 Coding, (AMRN-PEXP-0011146 – AMRN-PEXP-0011163)
		236		Redline of Kornak V3 & V5 Calculations, (AMRN-PEXP-0011164 – AMRN-PEXP-0011186)

Date Marked	Date Admitted	Number	Witness	Description
		237		Casella & Berger, Statistical Inference (2d ed. 2002), (AMRN-PEXP-0011375 – AMRN-PEXP-0012053)
		238		Jacobian output R, (AMRN-PEXP-0012054 – AMRN-PEXP-0012055)
		239		Jacobian code, (AMRN-PEXP-0012056 – AMRN-PEXP-0012057)
		240		Jacobian code calculations, (AMRN-PEXP-0012058 – AMRN-PEXP-0012059)
		241		lavinV5 ICOSAPENT_DFNDT 00020683.R, (ICOSAPENT_DFNDT 00020683 – ICOSAPENT_DFNDT 00020683)
		242		lavinV3 ICOSAPENT_DFNDT 00020685.R, (ICOSAPENT_DFNDT 00020685 – ICOSAPENT_DFNDT 00020685)
		243		Email from B. Finkelstein re Corrected Reply Expert Report of John Kornak 6.13.2019

Date Marked	Date Admitted	Number	Witness	Description
		244		U.S. Centers for Disease Control National Health and Nutrition Examination Survey: Intake of Calories and Selected Nutrients for the United States Population, 1999–2000, (AMRN00206048 – AMRN00206049)
		245		U.S. Dept. of Agriculture, Average Daily Intake of Food by Food Source and Demographic Characteristics, 2007–10, (AMRN00206050 – AMRN00206052)
1/13/2020	1/13/2020	246		Oh et al., <i>Management of Hypertriglyceridemia</i> , 75 American Family Physician 1365 (2007), (AMRN01200251 – AMRN01200257)
		247		Amarin NDA 202057 – § 3.2.P.5 Control of Drug Product [VASCEPA, Capsules], (AMRN03137774 – AMRN03137781)
		248		Budoff, <i>Triglycerides and Triglyceride- Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease</i> , 118 Am. J. Cardiology 138 (2016), (AMRN03145671 – AMRN03145678)
		249		American College of Cardiology CardioSmart, <i>Very High Triglycerides</i> , <a href="https://www.cardiosmart.org/Heart-&lt;br/&gt;Conditions/High-Cholesterol/High-&lt;br/&gt;Cholesterol-Home/Very-High-&lt;br/&gt;Triglycerides">https://www.cardiosmart.org/Heart- Conditions/High-Cholesterol/High- Cholesterol-Home/Very-High- Triglycerides</a> , (AMRN-PEXP-0000366 – AMRN-PEXP-0000372)

Date Marked	Date Admitted	Number	Witness	Description
		250		Wright et al., <i>Dietary Intake of Ten Key Nutrients for Public Health</i> , United States: 1999–2000, Advance Data From Vital & Health Statistics, No. 334 (Apr. 17, 2003), available at: <a href="https://www.cdc.gov/nchs/data/ad/ad334.pdf">https://www.cdc.gov/nchs/data/ad/ad334.pdf</a> , (AMRN-PEXP-0000373 – AMRN-PEXP-0000376)
		251		Guyatt et al., <i>Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine</i> , 268 JAMA 2420 (1992), (AMRN-PEXP-0000377 – AMRN-PEXP-0000382)
		252		Sackett et al., <i>Evidence Based Medicine: What It Is and What It Isn't</i> , 312 BMJ 71 (1996), (AMRN-PEXP-0000383 – AMRN-PEXP-0000384)
		253		Budoff et al., <i>Effect of Vascepa (Icosapent Ethyl) on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides (200–499 mg/dL) on Statin Therapy: Rationale and Design of the EVAPORATE Study</i> , 41 Clinical Cardiology 13 (2018), (AMRN-PEXP-0000385 – AMRN-PEXP-0000391)
		254		Icosapent, Ethyl Capsule 1g, <i>Certificate of Analysis</i> , (DRLEEPA 0001632 – DRLEEPA 0001647)
		255		ANDA No. 209499, In-vitro - In-vivo Study Reports, (DRLEEPA 0002566 – DRLEEPA 0002705)

Date Marked	Date Admitted	Number	Witness	Description
		256		ANDA No. 209499 – § 5.3 Bioavailability/Bioequivalence, (DRLEEP A 0016051 – DRLEEP A 0016221)
		257		FDA Correspondence dated July 10, 2018, (DRLEEP A 0095538 – DRLEEP A 0097311)
1/13/2020	1/13/2020	258		Defendants Dr. Reddy's Laboratories, Inc., and Dr. Reddy's Laboratories, Ltd. Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-333), Civil No. 2:16-02525 (Oct. 15, 2018) <i>Stipulated</i>
1/13/2020	1/13/2020	259		Joint Stipulation Regarding Agreement that DRL's Proposed ANDA Product Meets Certain Claim Limitations Order, ECF No. 159, Civil No. 2:16-02525 (Dec. 3, 2018) <i>Stipulated</i>
		260		Amarin, <i>Amarin Announces Market Introduction of Vascepa (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (Jan. 24, 2013)</i> , <a href="https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-market-introduction-vascepa-icosapent-ethyl">https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-market-introduction-vascepa-icosapent-ethyl</a> , (WWICO-NV-074728 – WWICO-NV-074730)
1/13/2020	1/13/2020	261		Defendants' Responses to Plaintiffs' Requests for Admission (Nos. 1-129) (Oct. 12, 2018) <i>Stipulated</i>
		262		E-mail from M. Goodin to M. Kennedy et al. (Apr. 23, 2018)

Date Marked	Date Admitted	Number	Witness	Description
1/13/2020	1/13/2020	263		Side by Side Comparison of Previously Submitted Labeling and Proposed FPL Labeling, (WWIC0-NV-002845 – WWIC0-NV-0028454)  stipulated
		264		Amarin Certificate of Analysis for NDA 202057 by Banner – § 3.2.P.5 Control of Drug Product [AMR101, Capsules], (AMRN00186631 – AMRN00186658)
		265		Berglund et al., <i>Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline</i> 97 Journal of Clinical Endocrinology and Metabolism 2969 (2012), (AMRN02340783 – AMRN02340803)
1/13/2020	1/13/2020	266		NDA No. 202057, NDA Approval (Jul. 26, 2012), (AMRN02973175 – AMRN02973191)  stipulated
		267		LOVAZA® Prescribing Information (2010), (AMRN03059150 – AMRN03059159)
		268		Baigent et al., <i>Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins</i> , 366 Lancet 1267 (2005), (AMRN03130228 – AMRN03130239)
1/14/2020	1/14/2020	269	Budoff	Miller et al., <i>Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association</i> , 123 Circulation 2292 (2011), (AMRN03146607 – AMRN03146649)

Date Marked	Date Admitted	Number	Witness	Description
		270		Amarin Pharma Inc., <i>Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR 101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of Cardiovascular Events with EPA — Intervention Trial)</i> (draft) (Jan. 29, 2019), (AMRN03164813 – AMRN03165069)
1/17/2020	1/17/2020	271	Fisher	Amarin Pharma Inc., <i>Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of Cardiovascular Events with EPA — Intervention Trial)</i> (ver. 1.0) (Feb. 27, 2019), (AMRN03168530 – AMRN03168883)
1/13/2020	1/13/2020	272	Ketchum	Bhatt et al., <i>Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia</i> , 380 N. Engl. J. Med. 11 (2019), (AMRN-PEXP-0000689 – AMRN-PEXP-0000700)
1/13/2020	1/13/2020	273		ANDA No. 209457, Submission of ANDA Application No. 209457, (WWIC0-NV-000049 – WWIC0-NV-000052)
1/13/2020	1/13/2020	274		ANDA No. 209457, Proposed Prescribing Information (Revised December 2016), (WWIC0-NV-002835 – WWIC0-NV-002843)
Same as 1700 1741700 admitted by stipulation				

Date Marked	Date Admitted	Number	Witness	Description
		275		FDA, "Combating Antibiotic Resistance," available at <a href="https://www.fda.gov/consumers/consumer-updates/combating-antibiotic-resistance">https://www.fda.gov/consumers/consumer-updates/combating-antibiotic-resistance</a> , (AMRN-PEXP-0009113 – AMRN-PEXP-0009116)
		276		Jackowski et al., <i>Provision of Lifestyle Counseling and the Prescribing of Pharmacotherapy for Hyperlipidemia Among US Ambulatory Patients: A National Assessment of Office-Based Physician Visits</i> , 18 Am. J. Cardiovascular Drugs 65 (2017), (AMRN-PEXP-0009303 – AMRN-PEXP-0009309)
1/14/2020	1/14/2020	277	Budoff	Jacobson et al., <i>National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report</i> , 9 J. of Clinical Lipidology 129 (2015), (AMRN-PEXP-0009310 – AMRN-PEXP-0009350)
		278		Pejic, <i>Should We Treat Moderately Elevated Triglycerides? Yes: Treatment of Moderately Elevated Triglycerides Is Supported by the Evidence</i> [Editorial], 83 Am. Family Physician 1 (2011), (AMRN-PEXP-0009488 – AMRNPEXP-0009489)
<i>Hasbullah</i>	<i>Hasbullah</i>	279		Reilly, <i>The Essence of EBM: Practicing What We Teach Remains a Big Challenge</i> , 329 BMJ 991 (2004), (AMRN-PEXP-0009511 – AMRN-PEXP-0009512)

Date Marked	Date Admitted	Number	Witness	Description
		280		Grundy et al., 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol, American College of Cardiology (2018), <a href="https://www.acc.org/latest-in-cardiology/ten-pointstoremember/2018/11/09/14/28/2018-guideline-on-management-of-blood-cholesterol">https://www.acc.org/latest-in-cardiology/ten-pointstoremember/2018/11/09/14/28/2018-guideline-on-management-of-blood-cholesterol</a> , (AMRN-PEXP-0010618 – AMRN-PEXP-0010737)
		281		Pejic et al., Hypertriglyceridemia, 19 J. Am. Board Fam Med 310 (2006), (AMRN-PEXP-0010738 – AMRN-PEXP-0010744)
		282		Willson et al., Ethnicity/Race, Use of Pharmacotherapy, Scope of Physician-Ordered Cholesterol Screening, and Provision of Diet/Nutrition or Exercise Counseling during US Office-Based Visits by Patients with Hyperlipidemia, 10 American Journal of Cardiovascular Drugs 105 (2010), (AMRN-PEXP-0010745 – AMRN-PEXP-0010753)
		283		LAMISIL® Prescribing Information (2019), (ICOSAPENT_DFNDT00015617 – ICOSAPENT_DFNDT00015629)
		284		LEVAQUIN® Prescribing Information (2018), (ICOSAPENT_DFNDT00015630 – ICOSAPENT_DFNDT00015687)
1/14/2020	1/14/2020	285	Poudel, S.	LOVENOX® Prescribing Information (2018), (ICOSAPENT_DFNDT00015711 – ICOSAPENT_DFNDT00015751)

Date Marked	Date Admitted	Number	Witness	Description
1/13/2020		286	Ketchum	VASCEPA DTC TV Advertisement Script, (AMRN03149719 – AMRN03149723)
1/13/2020	1/13/2020	287	Ketchum	Vascepa® Print Advertisement, (AMRN03149773 – AMRN03149774)
1/14/2020	1/14/2020	288	Bodoff	Karalis et al., <i>A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids</i> , 34 Adv Ther 300, 309, (AMRN-PEXP-0001515 – AMRN-PEXP-0001538)
1/13/2020	1/13/2020	289	Ketchum	NDA No. 202057, Medical Review(s) (Jul. 25, 2012), (ICOSAPENT_DFNDT00015424 – ICOSAPENT_DFNDT00015567)  Samuel 1701
		290		LOVAZA® Prescribing Information (2014), (ICOSAPENT_DFNDT00016641 – ICOSAPENT_DFNDT00016653)
1/13/2020	1/13/2020	291		Notice of Deposition 30(b)(6)
1/13/2020	1/13/2020	292		Notice of Deposition of Andrea Cady

Date Marked	Date Admitted	Number	Witness	Description
		293		Section 3.2.P.5.3 of ANDA 209457: Validation of Analytical Procedures, (WWIC0-NV-001211 – WWIC0-NV-001347)
1/13/2020	1/13/2020	294		Module 2: Quality Overall Summary Roxane Laboratories Inc., (WWIC0-NV-000164 – WWIC0-NV-000179)
		295		Section 3.2.S.4.1 of ANDA 209457: Specification, (WWIC0-NV-000427 – WWIC0-NV-000430)
		296		Section 3.2.S.4.2 of ANDA 209457: Analytical Procedures, (WWIC0-NV-000431 – WWIC0-NV-000484)
		297		Section 3.2.S.4.3 of ANDA 209457: Validation of Analytical Procedures, (WWIC0-NV-000485 – WWIC0-NV-000656)
		298		Section 3.2.S.4.4 of ANDA 209457: Batch Analysis, (WWIC0-NV-000657 – WWIC0-NV-000686)
		299		Section 3.2.P.1 of ANDA 209457: Description and Composition of the Drug Product, (WWIC0-NV-000719 – WWIC0-NV-000721)

Date Marked	Date Admitted	Number	Witness	Description
		300		Section 3.2.P.2 of ANDA 209457: Pharmaceutical Development, (WWIC0-NV-000722 – WWIC0-NV-000880)
		301		Section 3.2.P.5.1 of ANDA 209457: Specifications, (WWIC0-NV-001158 – WWIC0-NV-001160)
		302		Section 3.2.P.5.2 of ANDA 209457: Analytical Procedures, (WWIC0-NV-001161 – WWIC0-NV-001210)
		303		Section 3.2.P.5.4 of ANDA 209457: Batch Analysis, (WWIC0-NV-001348 – WWIC0-NV-001371)
		304		Section 3.2.P.8.1 of ANDA 209457: Stability Summary and Conclusion, (WWIC0-NV-001439 – WWIC0-NV-001459)
		305		Stability Data Icosapent Ethyl (West-Ward) (Sept. 6, 2016), (WWIC0-NV-002692 – WWIC0-NV-002702)
		306		Information Request to T. Adams from: S. Smith and Related Communication (June 15, 2017), (WWIC0-NV-099968 – WWIC0-NV-099993)

Date Marked	Date Admitted	Number	Witness	Description
1/13/2020	1/13/2020	307		Email from J. McGlone to T. Miller et al. (Dec. 3, 2012), (WWICO-MV-093674 – WWICO-MV-093692)
1/13/2020	1/13/2020	308		Email from J. McGlone to Dr. S. Uraizee (Nov. 26, 2012), (WWICO-NV-093693 – WWICO-NV-093712)
		309		Specification for Icosapent Ethyl (West-Ward) (June 13, 2017), (WWICO-NV-1000023 – WWICO-NV-1000025)
		310		Finished Products Test Method and Related Documents (June 13, 2017), (WWICO-NV-1000026 – WWICO-NV-1000040)
		311		Amarin Pharma Inc., <i>Drug Substance</i> , (AMRN00000225 – AMRN00000238)
		312		Amarin Pharma Inc., <i>Comparison of Related Substances in Drug Substance Batches and Corresponding AMR101 Capsule, 1 g Batches</i> (5/14/2009), (AMRN00000491 – AMRN00000491)
		313		Amarin Pharma Inc., <i>Control of Drug Substance</i> (5/14/2009), (AMRN00000585 – AMRN00000595)
		314		Amarin Pharma Inc., <i>Comparison of Related Substances in Drug Substance Batches and Corresponding AMR101 Capsule, 1 g Batches</i> (5/13/2009), (AMRN00020568 – AMRN00020568)

Date Marked	Date Admitted	Number	Witness	Description
		315		IND 102457-s0046, 2.3.P.5 Control of Drug Product, (AMRN00100895 – AMRN00100908)
		316		NDA No. 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Nisshin Pharma Inc.], (AMRN00115239 – AMRN00115243)
		317		NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Justification of Specifications, (AMRN00116059 – AMRN00116073)
		318		NDA 202057, 2.3.P.2 Pharmaceutical Development [AMR101, Capsules], (AMRN00186470 – AMRN00186479)
		319		NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Batch Analysis, (AMRN00189290 – AMRN00189301)
		320		NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Chempart, Inc.], (AMRN00189740 – AMRN00189740)
		321		NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, BASF], (AMRN00190387 – AMRN00190387)
		322		NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Finorga], (AMRN00199987 – AMRN00199987)

Date Marked	Date Admitted	Number	Witness	Description
		323		NDA 202057, 3.2.P.5.4 Batch Analysis, (AMRN00200042 – AMRN00200043)
		324		NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Nisshin Pharma Inc.], (AMRN00200627 – AMRN00200627)
		325		NDA 202057, 3.2.P.5 Control of Drug Product [VASCEPA, Capsules], Batch Analysis, (AMRN03133712 – AMRN03133722)
		326		NDA 202057, 1.13.5 Summary of Manufacturing Changes, (AMRN03136091 – AMRN03136094)
		327		NDA 202057, 2.3.P.5 Control of Drug Product [VASCEPA, Capsules], (AMRN03137600 – AMRN03137637)
		328		NDA 202057, 3.2.P.5 Control of Drug Product [VASCEPA, Capsules], Analytical Procedures, (AMRN03137782 – AMRN03137805)
		329		NDA 202057, 3.2.P.5.4 Batch Analysis, (AMRN03137854 – AMRN03137856)
		330		ANDA 209499, <i>In-Vitro Dissolution Data</i> , (DRLEEP A 0000325 – DRLEEP A 0000357)

Date Marked	Date Admitted	Number	Witness	Description
		331		Dr. Reddy's, Module 3 Quality — 3.2.P.2 Pharmaceutical Development, (DRLEEEPA 0003860 – DRLEEEPA 0003965)
		332		ANDA 209499, 5.3 <i>Bioavailability/Bioequivalence</i> , (DRLEEEPA 0004209 – DRLEEEPA 0004379)
		333		<i>Certificate of Analysis: Analytical Testing of Icosapent Ethyl Capsule 1 gram</i> (Lot No. 2J00034), (DRLEEEPA 0011662 – DRLEEEPA 0011665)
		334		<i>Certificate of Analysis: Analytical Testing of Icosapent Ethyl Capsule 1 gram</i> (Lot No. 2J00045) (Mar. 2013), (DRLEEEPA 0011666 – DRLEEEPA 0011669)
		335		<i>Certificate of Analysis: Analytical Testing of Icosapent Ethyl Capsule 1 gram</i> (Lot No. 2K00243) (Dec. 2013), (DRLEEEPA 0013530 – DRLEEEPA 0013534)
		336		NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Analytical Procedures, (AMRN00186607 – AMRN00186630)
		337		NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Justification of Specifications, (AMRN00186666 – AMRN00186683)
		338		NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Justification of Specifications, (AMRN00188964 – AMRN00188981)

Date Marked	Date Admitted	Number	Witness	Description
		339		NDA 202057, 3.2.P.5.1-2 Specifications for VASCEPA Capsules, 1g, (AMRN03137779 – AMRN03137781)
		340		ANDA 209457, 2.3 Quality Overall Summary (QOS), (WWICO-NV-000196 – WWICO-NV-000225)
		341		<i>Certificate of Analysis: Icosapent Ethyl Capsules, 1 gram (Lot No. 1569547), (WWIC0-NV-000405 – WWIC0-NV-000408)</i>
		342		<i>Certificate of Analysis: Vascepa (Lot No. 2J00045), (WWIC0-NV-000409 – WWIC0-NV-000410)</i>
		343		West-Ward, Pharmaceutical Development Report of Icosapent Ethyl Capsules, 1 gram, (July 2016), (WWIC0-NV-000724 – WWIC0-NV-000790)
		344		<i>Certificates of Analysis: Icosapent Ethyl Capsules, 1 g (Lot Nos. 1362418, 1463425, 1569547), (WWIC0-NV-001349 – WWIC0-NV-001371)</i>
		345		<i>Certificate of Analysis: Vascepa (Lot No. 2K00056), (WWICO-NV-023240 – WWICO-NV-023240)</i>
		346		<i>Certificate of Analysis: Vascepa (Lot No. 2K00067), (WWICO-NV-023241 – WWICO-NV-023241)</i>

Date Marked	Date Admitted	Number	Witness	Description
		347		<i>Certificate of Analysis: Ethyl Icosapentate (Icosapent Ethyl) (Lot No. 05264002), (WWICO-NV-122070 – WWICO-NV-122071)</i>
		348		ANDA 206264, 2.7.1.2 Summary of Results of Individual Studies, (WWICO-NV-158523 – WWICO-NV-158537)
		349		<i>Certificates of Analysis: Icosapent Ethyl Capsules, 1 g (Lot Nos. 1362418, 1463425, 1569547), (WWICO-NV-162334 – WWICO-NV-162360)</i>
		350		<i>Certificates of Analysis: Icosapent Ethyl Capsules, 1 g (Lot Nos. 3079110, 3368301, 3368523), (WWICO-NV-162361 – WWICO-NV-162376)</i>
		351		West-Ward, <i>Certificate of Analysis: Vascepa (Lot No. 5B01002), (WWICO-NV-162377 – WWICO-NV-162378)</i>
		352		<i>Certificate of Analysis: Vascepa (Lot. No. 6F01860), (WWICO-NV-162384 – WWICO-NV-162386)</i>
		353		<i>Certificate of Analysis: Vascepa (Lot No. 6F01871), (WWICO-NV-162387 – WWICO-NV-162389)</i>
		354		<i>Certificates of Analysis: Icosapent Ethyl (Lot Nos. 37662, 61268, 61269, 61271), (WWICO-NV-162390 – WWICO-NV-162405)</i>

Date Marked	Date Admitted	Number	Witness	Description
		355		<i>Certificate of Analysis: Icosapent Ethyl Capsules, 1 gram (Lot. No. 3368523), (WWICO-NV-162410 – WWICO-NV-162413)</i>
		356		NDA 202057, 3.2.P.5.4 Batch Analysis, (AMRN03137859 – AMRN03137860)
		357		Table of Contents, Specificity of Additional Impurities, (WWICO-NV-100000 – WWICO-NV-100012)
		358		Executed Errata Sheet for the February 15, 2018 Deposition of Michael Miller
		359		Executed Errata Sheet for the July 1, 2019 Deposition of Carl Peck
		360		Executed Errata Sheet for the July 10, 2019 Deposition of Peter P. Toth
		361		Executed Errata Sheet for the July 17, 2019 Deposition of Matthew Budoff
		362		Executed Errata Sheet for the July 2, 2019 Deposition of Sean Nicholson

Date Marked	Date Admitted	Number	Witness	Description
		363		Executed Errata Sheet for the June 19, 2019 Deposition of R. Preston Mason
		364		Executed Errata Sheet for the June 20, 2019 Deposition of Stephen Kunin
		365		Executed Errata Sheet for the June 25, 2019 Deposition of Firhaad Ismail
		366		Executed Errata Sheet for the November 5, 2018 Deposition of Harold Bays
		367		Executed Errata Sheet for the November 5, 2018 Deposition of Ian Osterloh
		368		Executed Errata Sheet for the October 16, 2018 Deposition of Aaron Berg
		369		Executed Errata Sheet for the October 24, 2018 Deposition of Steven Ketchum
		370		Executed Errata Sheet for the October 30, 2018 Deposition of Rebecca Juliano

Date Marked	Date Admitted	Number	Witness	Description
		371		Executed Errata Sheet for the September 14, 2018 Deposition of Howard Weintraub
		372		Executed Errata Sheet for the September 21, 2018 Deposition of Philip Lavin
1/17/2020	1/17/2020	373	Fisher	Chapman et al., <i>Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management</i> , European Heart Journal (2011) 32, 1345-1361
		374		Feingold et al., <i>Diabetes and Dyslipidemia</i> , Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000
		375		Siscovick et al., <i>Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease</i> , 135 Circulation e867 (2017), (ICOSAPENT_DFNDT00018006 – ICOSAPENT_DFNDT00018023)
1/13/2020	1/13/2020	376		Kurabayashi et al., <i>Eicosapentaenoic Acid Effect on Hyperlipidemia in Menopausal Japanese Women</i> , 96 The American College of Obstetricians and Gynecologists 521 (2000), (ICOSAPENT_DFNDTS00006237 – ICOSAPENT_DFNDTS00006244)
		377		Same as 134 USPTO Office Communication (June 20, 2011), (AMRN03058824 – AMRN03058835)